Study #2018-0345
A Personalized Vaccine for the Immune Prevention of Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Lenalidomide, Vaccine Therapy
Description
This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
Information and next steps
Disease:
Smoldering Plasma Cell Myeloma
Study phase:
I (Early)
Physician name:
Elisabet Manasanch
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.